Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma
Abstract
Abstract This study assessed real-world effectiveness and safety of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including those with high-risk disease, secondary central nervous system (sCNS) involvement, comorbidities, and poor fitness, using data in the Center for International Blood and Marrow Transplant Research Registry from 5 February 2021 to 4 February 2025. Eligible patients (N = 1116) received liso-cel and had ≥1 effectiveness and safety assessment after infusion, including 195 in the second-line setting, 71 with sCNS, and 257 with transformed LBCL. Median age was 71.1 years (range, 21.5-91.2), with 72.3% aged ≥65 years. Within the overall population, 6.6% had an Eastern Cooperative Oncology Group performance status of ≥2, 53.4% had ≥1 comorbidity, and the median number of previous lines of therapy was 3 (range, 1-16). Median study follow-up was 12.6 months (95% confidence interval [CI], 12.5-12.8). Among effectiveness-evaluable patients (n = 1109), objective response rate was 81.2% and complete response rate was 71.3%. Duration of response, progression-free survival, and overall survival rates at 12 months were 60.2% (95% CI, 56.4-63.9), 51.2% (95% CI, 48.0-54.4), and 67.6% (95% CI, 64.5-70.6), respectively. Cytokine release syndrome was reported in 51.0% of patients, with grade ≥3 events in 2.5%. Immune effector cell–associated neurotoxicity syndrome was reported in 26.6% of patients, with grade ≥3 events in 9.2%. The 12-month nonrelapse mortality rate was 6.1% (95% CI, 4.6-7.8). These real-world data reinforce the effectiveness and safety of liso-cel in this broad population of patients with R/R LBCL, including younger patients and those with high-risk disease features.
Article Details
Authors (26)
Jennifer L. Crombie
1Dana-Farber Cancer Institute, Boston, MA
Sairah Ahmed
2Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX
Matthew J. Frigault
3Massachusetts General Hospital, Boston, MA
Bradley D. Hunter
4Intermountain LDS Hospital, Salt Lake City, UT
M. Lia Palomba
5Memorial Sloan Kettering Cancer Center, New York, NY
Abu-Sayeef Mirza
6Moffitt Cancer Center, Tampa, FL
Matthew Lunning
Department of Internal Medicine, Division of Oncology and Hematology, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center and Nebraska Medicine, Omaha
Ogechukwu Egini
8Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Maria Silvina Odstrcil Bobillo
9Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT
Avyakta Kallam
10Duarte Cancer Center, City of Hope Medical Center, Duarte, CA
Swetha Kambhampati Thiruvengadam
10Duarte Cancer Center, City of Hope Medical Center, Duarte, CA
Dasom C. Lee
11Stanford University School of Medicine, Stanford, CA
Saurabh Dahiya
Mehdi Hamadani
12Blood and Marrow Transplant and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI
Alex F. Herrera
10Duarte Cancer Center, City of Hope Medical Center, Duarte, CA
Catherine J. Lee
13Fred Hutchinson Cancer Center, University of Washington, Seattle, WA
Krish Patel
C. U. Shah Medical College, Surendranagar, India
Sagar S. Patel
15Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT
Patrick M. Reagan
16University of Rochester Medical Center, Rochester, NY
Mazyar Shadman
David Bernasconi
17Bristol Myers Squibb, Boudry, Switzerland
Soyoung Kim
Fei Fei Liu
19Bristol Myers Squibb, Princeton, NJ
Debasmita Roy
19Bristol Myers Squibb, Princeton, NJ
Marcelo C. Pasquini
18Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
Iris Isufi